2022 Volume 47 Issue 2 Pages 83-89
From April 2020, genetic testing for BRCA mutations for diagnosing hereditary breast and ovarian cancer (HBOC) in breast cancer patients, risk-reducing mastectomy, and risk-reducing salpingo-oophorectomy in BRCA mutation carriers began to be covered by the National Health Insurance in Japan, so that medical treatment of HBOC has reached a turning point. We examined the current status and issues in 11 surgical cases of BRCA mutation carriers after insurance coverage at our hospital. Out of the 11 cases, only surgery for primary breast cancer was performed in 5 cases, and various procedures, depending on the individual situations, were performed in the remaining patients. It is necessary to secure a surgical frame depending on the surgical procedure, and building a system for surgery across other departments is a future task. In addition, as the number of genetic tests for BRCA is expected to increase further in the future, it is important that there is smooth cooperation among not only the breast surgeons, but also among breast surgeons, gynecologists, plastic surgeons, and genetic counselors for patients who have just been diagnosed with cancer or HBOC, so as to ensure that the best surgical decisions are made within a relatively shorter period of time.
